- Home
- MBOT vs YARW Comparison
MBOT vs YARW Comparison
Compare MBOT & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | YARW |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9M | 114.6M |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MBOT | YARW |
|---|---|---|
| Price | $1.31 | $27.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 440.0K | 110.6K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,887.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $24.00 |
| 52 Week High | $3.47 | $44.28 |
Technical Indicators
Market Signals| Indicator | MBOT | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 43.29 |
| Support Level | N/A | $24.00 |
| Resistance Level | $2.20 | $32.89 |
| Average True Range (ATR) | 0.05 | 2.80 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 44.04 | 48.72 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.